Odivo Patient Assistance Program Updated, Annual Out-of-Pay Ratio Drops By More Than 75%

On December 24, 2020, the China Cancer Foundation (CFC) announced today that the Odivo Patient Assistance Program will be updated again, with the program being adjusted from the original "First 3 plus 3, Follow-up 3 plus 4 Cycles" to annual "3 plus" 3, follow-up 3 plus X", that is, patients who meet the project criteria, in the application year to pay a maximum of 6 out-of-the-way Odivo treatment costs, you can obtain all the remaining drug assistance in the application year, patients can be in accordance with the application year repeated application for assistance until the end of the project or disease progression.
under the new scheme, the annual out-of-account ratio of patients fell by more than 75% from the highest market price, further reducing the financial burden of treating diseases.
As the first and currently the only PD-1 inhibitor approved for second-line non-small cell lung cancer, platinum-containing treatment of advanced head and neck squamous cancer, and two or more systemic treatment of advanced stomach cancer, Odevo is currently the only immuno-oncology drug in China to initiate patient assistance programs in the above three adaptation certificates.
this adjustment, patients who benefit will be able to use imported immuno-oncology drugs throughout the year for only a 1/4 of the market price, and the accessability of innovative drugs will be further enhanced, with more patients expected to achieve high-quality long-term survival.
-adjusted Patient Assistance Program will be effective from 1 January 2021 and all eligible low-income patients can apply in accordance with the requirements and procedures.
requirements of the adjusted project application materials and the specific project process, please pay attention to the official website information of the China Cancer Foundation (), or call the project hotline 400-669-0906 for consultation.
To reduce the initial treatment pressure and reduce the cost of treatment throughout the year, in line with the consistent purpose of the China Cancer Foundation, in order to further improve the access to innovative cancer drugs, the Foundation, with the support of the aid company Shishi Shiguibao, the Foundation has made a number of adjustments to the Odivo Patient Assistance Program.
the beginning of this year, the economic threshold for first-time treatment was lowered, allowing more patients to try innovative cancer immunotherapy for long-term survival.
, the project was adjusted again, which is expected to further reduce the financial pressures faced by patients during treatment and improve access to medication.
, Director of the China Cancer Foundation, said: "In recent years, immuno-oncology as an innovative treatment has provided patients with new treatment options.
the original patient assistance program to some extent to reduce the financial pressure on patients, but there are still patients for financial reasons can not complete long-term standardized treatment.
updated programme further reduces the annual cost of treatment for patients on the basis of reducing the financial stress of initial treatment, allowing benefiting patients to continue to receive assistance drugs without giving up treatment for financial reasons and maximizing the effectiveness of immunotherapy.
" patients can choose to be given in kilogram weight (3 mg/kg) or in a fixed dose (240 mg) depending on their individual circumstances.
In the case of 60 kg of patients, for example, the out-of-the-way cost of completing a year's treatment (once every two weeks) would be about RMB479,492 million, while in the new scheme, the annual out-of-the-money cost of patients would be RMB110,652, about a <2>% of the listed price.
multi-party efforts to jointly improve patient access to malignant tumors has become one of the major public health problems seriously threatening people's health, the latest statistics of the National Cancer Center show that the incidence of malignant tumors is increasing at an annual rate of 3.9%.
face of persistent high incidence of cancer, traditional treatment methods can not meet the growing demand for treatment, immuno-oncology treatment as an innovative treatment for patients to bring new hope for long-term survival.
June 2018, Odivo was approved for sale in China, becoming the first immuno-oncology drug to land in China, opening a new chapter in cancer treatment.
, however, as an innovative treatment, even with patient assistance programs, patients still face greater financial pressure in the treatment process.
to improve this situation, all sectors of society are working together to explore innovative payment models to improve patient access to innovative drugs by building a multi-level health care system. Ms. Chen Siyuan,
Shishi Mei Shiguibao Chinese mainland and Regional General Manager of Hong Kong, said, "In keeping with our long-term commitment to China, Shishi Shiguibao recently formulated the 'China Strategy 2030' plan, in addition to accelerating the bringing of global innovative drugs to China, the company will actively work closely with the government and related partners to further enhance Odivo's access to China through innovative access models and differentiated patient support services."
, 46 cities have incorporated Odivo into local supplementary medical insurance or commercial insurance, including Zhuhai, Foshan, Guangzhou, Dalian, Suzhou and other 11 cities to allow patients to take out medical insurance.
believe that with the joint efforts of all of you, patients will be able to improve access to innovative medicines in a more appropriate, rapid and sustainable way in the future.
"medsci Source: medsci Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here